Skip to main content
رجوع
RGEN logo

Repligen Corporation

جودة البيانات: 100%
RGEN
NASDAQ Healthcare Medical - Instruments & Supplies
KWD 116.35
▲ KWD 2.47 (2.17%)
القيمة السوقية: 6.55B
نطاق اليوم
KWD 116.25 KWD 122.00
نطاق 52 أسبوعًا
KWD 102.97 KWD 175.77
حجم التداول
807,765
متوسط 50 يوم / 200 يوم
KWD 140.91 / KWD 138.89
الإغلاق السابق
KWD 113.88

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 134.1 0.4
P/B 3.1 2.9
ROE % 2.4 3.7
Net Margin % 6.6 3.9
Rev Growth 5Y % 2.4 10.0
D/E 0.3 0.2

السعر المستهدف للمحللين

Hold
KWD 177.500 +52.6%
Low: KWD 150.000 High: KWD 200.000
مكرر الربحية المستقبلي
58.5
ربحية السهم المستقبلية
KWD 1.988
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
830 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 5.690
KWD 5.542 – KWD 5.787
1.5 B 1
FY2029 KWD 4.487
KWD 4.370 – KWD 4.563
1.3 B 1
FY2028 KWD 3.304
KWD 2.644 – KWD 3.791
1.1 B 5

النقاط الرئيسية

Revenue grew 2.43% annually over 5 years — modest growth
ROE of 2.40% is below average
Debt/Equity of 0.33 — conservative balance sheet
Generating 93.90M in free cash flow
P/E of 134.05 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 13.93%

النمو

Revenue Growth (5Y)
2.43%
Revenue (1Y)16.36%
Earnings (1Y)N/A
FCF Growth (3Y)11.94%

الجودة

Return on Equity
2.40%
ROIC1.60%
Net Margin6.62%
Op. Margin8.07%

الأمان

Debt / Equity
0.33
Current Ratio8.37
Interest Coverage2.57

التقييم

P/E Ratio
134.05
P/B Ratio3.11
EV/EBITDA112.09
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.36% Revenue Growth (3Y) 8.05%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 17.20%
Revenue Growth (5Y) 2.43% Earnings Growth (5Y) -21.43%
Profitability
Revenue (TTM) 738.26M Net Income (TTM) 48.89M
ROE 2.40% ROA 1.66%
Gross Margin 47.09% Operating Margin 8.07%
Net Margin 6.62% Free Cash Flow (TTM) 93.90M
ROIC 1.60% FCF Growth (3Y) 11.94%
Safety
Debt / Equity 0.33 Current Ratio 8.37
Interest Coverage 2.57 Dividend Yield 0.00%
Valuation
P/E Ratio 134.05 P/B Ratio 3.11
P/S Ratio 8.88 PEG Ratio -0.65
EV/EBITDA 112.09 Dividend Yield 0.00%
Market Cap 6.55B Enterprise Value 6.68B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 738.26M 634.44M 632.36M 801.54M 670.53M
Net Income 48.89M -25.51M 35.60M 185.96M 128.29M
EPS (Diluted) 0.86 -0.46 0.63 3.24 2.24
Gross Profit 347.62M 274.65M 278.44M 455.71M 391.25M
Operating Income 59.58M -35.11M 47.70M 224.67M 167.25M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.95B 2.83B 2.83B 2.53B 2.36B
Total Liabilities 843.57M 856.95M 866.34M 620.90M 608.29M
Shareholders' Equity 2.11B 1.97B 1.96B 1.91B 1.75B
Total Debt 689.95M 686.25M 711.80M 422.96M 366.05M
Cash & Equivalents 566.02M 757.36M 751.32M 523.46M 603.81M
Current Assets 1.14B 1.07B 1.11B 998.12M 931.68M
Current Liabilities 135.83M 126.79M 164.94M 404.20M 375.26M